The approval of Eli Lilly's Alzheimer's treatment in China is a significant regulatory milestone, likely to enhance its market presence and increase revenue potential in a large market. This approval follows a similar approval for a competing product, indicating a growing acceptance and demand for Alzheimer's treatments in China.